Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (181-190 of 250) with videos related to

Pageof 25
Sort By:
Neurology|December 17, 2020
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary AnalysesRalph H B Benedict, Davorka Tomic, Bruce A Cree, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2020
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosisBruce Ac Cree, Baldur Magnusson, Nicolas Rouyrre, et al.
Multiple Sclerosis and Related Disorders|January 23, 2025
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudyPatrick Vermersch, Ralf Gold, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2022
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 yearsBruce Ac Cree, Douglas L Arnold, Robert J Fox, et al.
Multiple Sclerosis and Related Disorders|December 24, 2022
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidenceCelia Oreja-Guevara, Wallace Brownlee, Elisabeth G Celius, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 12, 2013
Milder multiple sclerosis course in patients with concomitant inflammatory bowel diseaseHélène Zéphir, Corinne Gower-Rousseau, Julia Salleron, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 19, 2025
European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?Jérôme de Seze, Chiara Zecca, Giovanni Castelnovo, et al.
European Journal of Neurology|June 22, 2026
Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO TrialPatrick Vermersch, Ralph H B Benedict, Bart Van Wijmeersch, et al.
Therapeutic Advances in Neurological Disorders|August 4, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS StudyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Journal of Clinical Apheresis|May 6, 2020
Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosisBruno Brochet, Mathilde Deloire, Christine Germain, et al.
Pageof 25

Showing results (181-190 of 250) with videos related to

Sort By:
Pageof 25
Neurology|December 17, 2020
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary AnalysesRalph H B Benedict, Davorka Tomic, Bruce A Cree, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2020
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosisBruce Ac Cree, Baldur Magnusson, Nicolas Rouyrre, et al.
Multiple Sclerosis and Related Disorders|January 23, 2025
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudyPatrick Vermersch, Ralf Gold, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2022
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 yearsBruce Ac Cree, Douglas L Arnold, Robert J Fox, et al.
Multiple Sclerosis and Related Disorders|December 24, 2022
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidenceCelia Oreja-Guevara, Wallace Brownlee, Elisabeth G Celius, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 12, 2013
Milder multiple sclerosis course in patients with concomitant inflammatory bowel diseaseHélène Zéphir, Corinne Gower-Rousseau, Julia Salleron, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 19, 2025
European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?Jérôme de Seze, Chiara Zecca, Giovanni Castelnovo, et al.
European Journal of Neurology|June 22, 2026
Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO TrialPatrick Vermersch, Ralph H B Benedict, Bart Van Wijmeersch, et al.
Therapeutic Advances in Neurological Disorders|August 4, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS StudyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Journal of Clinical Apheresis|May 6, 2020
Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosisBruno Brochet, Mathilde Deloire, Christine Germain, et al.
Pageof 25